Study guide
15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion
Key Takeaways Explain This Topic AI
The FDA has approved seven first-line pharmacotherapies for tobacco cessation: five nicotine replacement therapy (NRT) formulations (transdermal patch, gum, lozenge, oral inhaler, nasal spray), varenicline tartrate, and sustained-release bupropion hydrochloride.
Varenicline, an alpha-4 beta-2 nicotinic receptor partial agonist, produces the highest single-agent long-term abstinence rates (30% to 35% at 1 year), with definitive cardiovascular safety in acute coronary syndrome cohorts confirmed by the landmark EVITA and CATS trials.
Combination NRT—pairing a long-acting transdermal patch for baseline steady-state nicotine levels with a rapid-acting oral formulation (gum, lozenge, or inhaler) for breakthrough cravings—is clinically superior to any single NRT monotherapy.
Short-acting NRT dosing is dictated by Time to First Cigarette (TTFC): patients smoking within 30 minutes of waking require the 4 mg dose, and proper 'chew-and-park' technique is essential to facilitate buccal absorption and prevent gastrointestinal distress.
Bupropion SR inhibits neuronal reuptake of dopamine and norepinephrine, blunting cravings and post-cessation weight gain; it is strictly contraindicated in patients with seizure disorders, active eating disorders, or concurrent MAOI use.
Last updated: September 2026
15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion
Note
Guideline Recommendation : The ACC/AHA Secondary Prevention Guidelines and the USPHS Guidelines mandate that all tobacco-dependent patients undergoing cardiac rehabilitation be offered first-line pharmacotherapy unless medically contraindicated. Pharmacotherapy addresses the neurochemical dependence on nicotine, reducing craving intensity and withdrawal symptoms so patients can effectively engage in behavioral modification.
Nicotine dependence is driven by the neurobiological stimulation of alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptors in the ventral tegmental area (VTA) of the brain. Binding triggers rapid dopamine release in the nucleus accumbens , creating the classic neurochemical reward pathway. With chronic smoking, receptors upregulate and desensitize; abrupt cessation causes dopamine depletion, precipitating severe affective and somatic withdrawal symptoms. Pharmacologic therapies double to triple long-term cessation success, transforming 1-year unassisted quit rates of 3% to 5% into sustained abstinence rates of 25% to 35% .
First-Line Pharmacotherapy Options
The FDA has approved seven first-line pharmacotherapies: five formulations of Nicotine Replacement Therapy (NRT) , Varenicline , and Bupropion SR .
1. Nicotine Replacement Therapy (NRT)
NRT provides controlled, medicinal nicotine delivery without the toxic carbon monoxide, oxidant gases, carcinogens, or tar particulates present in combustible tobacco smoke. By preventing abrupt plasma nicotine troughs, NRT attenuates withdrawal cravings.
Transdermal Nicotine Patch (Long-Acting)
Pharmacokinetics : Continuous, slow transdermal absorption reaching steady-state plasma concentrations over 4 to 9 hours. Provides flat, consistent baseline blood levels over 16 to 24 hours.
Standard Step-Down Dosing Schedules :
Heavy Smokers (>10 cigarettes/day or >half pack) :
Step 1 (21 mg/day) for 4 to 6 weeks.
Step 2 (14 mg/day) for 2 weeks.
Step 3 (7 mg/day) for 2 weeks.
Light Smokers (≤10 cigarettes/day) :
Initiate therapy at Step 2 (14 mg/day) for 6 weeks, then step down to Step 3 (7 mg/day) for 2 to 4 weeks.
Application Instructions & Adverse Effects : Apply once daily in the morning to clean, dry, hairless skin on the upper body or outer arm; rotate sites daily to prevent contact dermatitis. If the patient experiences sleep disturbances or vivid dreams, advise removing the patch at bedtime (using a 16-hour wear schedule) or stepping down the patch strength.
Short-Acting NRT Formulations (Rescue Dosing)
Nicotine Gum & Lozenge :
Dose Stratification by Time to First Cigarette (TTFC) :
If the patient smokes their first cigarette within 30 minutes of waking : Prescribe the 4 mg dose (indicates high physiological dependence).
If the patient smokes more than 30 minutes after waking : Prescribe the 2 mg dose .
Chew-and-Park Technique for Gum : Chew slowly until a distinct peppery taste or tingling sensation appears (approximately 15–30 chews), then "park" the gum between the buccal mucosa and gum tissue to allow passive transmucosal absorption. When the tingle fades (after 1–2 minutes), chew again and park in a different location. Repeat over 30 minutes. Swallowing nicotine-rich saliva rapidly causes nausea, hiccups, dyspepsia, and throat irritation .
Acidic Beverage Restriction : Patients must avoid acidic beverages (such as coffee, carbonated sodas, citrus juices, wine, or energy drinks) for 15 minutes before and during the use of gum or lozenges, as an acidic oral pH prevents non-ionized nicotine absorption across the buccal mucosa.
Nicotine Oral Inhaler : Delivers nicotine vapor via buccal absorption upon puffing. Provides oral tactile stimulation that satisfies hand-to-mouth behavioral rituals. Recommended: 6 to 16 cartridges daily.
Nicotine Nasal Spray : Rapid mucosal absorption providing the fastest arterial nicotine rise among NRTs (venous-like peak within 5–10 minutes). Higher risk of nasal irritation and dependency; requires frequent dosing.
Combination NRT (Clinical Gold Standard)
Clinical practice guidelines strongly endorse combination NRT —pairing a long-acting transdermal patch (which supplies consistent baseline steady-state nicotine) with a short-acting agent (gum, lozenge, or inhaler taken prn for acute, breakthrough cravings). Multiple randomized meta-analyses confirm that combination NRT achieves significantly higher 6-month and 1-year abstinence rates than any single NRT monotherapy (odds ratio ~1.35 compared to patch alone).
Cardiovascular Safety of NRT
Historically, clinicians feared that NRT might trigger acute coronary events through hemodynamic stimulation. However, decades of clinical trials have proven that NRT is safe in patients with stable cardiovascular disease . Unlike cigarette smoke, NRT does not deliver carbon monoxide, does not cause carboxyhemoglobinemia, does not deliver oxidant free radicals, and produces blunted, gradual plasma nicotine curves without the sharp arterial spikes that trigger sudden catecholamine surges. While caution was traditionally advised in patients with unstable angina or within 2 weeks of acute MI, modern consensus panels endorse supervised NRT use in stabilized post-ACS patients when the alternative is continued combustible smoking.
- 2. Varenicline Tartrate (Chantix)
- Mechanism of Action
Varenicline is a synthetic small molecule that functions as a highly selective partial agonist at α4β2 neuronal nicotinic acetylcholine receptors :
Partial Agonist (Agonist Effect) : Binds to the receptor and stimulates moderate dopamine release (~40% to 60% of the maximum dopamine surge elicited by nicotine). This maintains baseline mesolimbic dopamine tone, effectively suppressing cravings and withdrawal symptoms.
Competitive Antagonist (Antagonist Effect) : Binds with exceptionally high affinity, occupying the receptor and competitively preventing nicotine from inhaled tobacco smoke from binding. If a patient lapses and smokes a cigarette, they experience no neurochemical reward or satisfaction , extinguishing the reinforcing behavior.
Clinical Dosing Titration
To minimize gastrointestinal adverse effects, varenicline requires a 1-week upward dose titration prior to the target quit date:
Days 1 to 3 : 0.5 mg orally once daily in the morning.
Days 4 to 7 : 0.5 mg orally twice daily (morning and evening).
Day 8 through Week 12 : 1.0 mg orally twice daily .
Treatment Duration : Standard course is 12 weeks. In patients who achieve complete abstinence at 12 weeks, an additional 12 weeks of maintenance therapy (24 weeks total) is recommended to prevent late relapse.
Landmark Clinical Trials & Cardiovascular Safety
EVITA Trial (Evaluation of Varenicline in Smoking Cessation After Acute Coronary Syndrome) : A landmark randomized, double-blind, placebo-controlled trial enrolling 302 patients across 24 hospitals. Varenicline was initiated in-hospital during admission for acute coronary syndrome (ACS) . At 24 weeks, continuous smoking abstinence was 35.8% in the varenicline group versus 25.8% in the placebo group (p < 0.05). Importantly, rates of Major Adverse Cardiovascular Events (MACE: cardiovascular death, recurrent MI, stroke, stent thrombosis) were identical between groups, verifying the safety of acute varenicline initiation in ACS.
CATS Trial (Cessation After Troponin S) : Further evaluated post-ACS cohorts, demonstrating robust efficacy without any signal of increased ventricular arrhythmias, recurrent ischemic hospitalization, or hemodynamic instability.
EAGLES Trial : Evaluated 8,144 smokers across 16 countries, comparing varenicline, bupropion, nicotine patch, and placebo in patients with and without psychiatric illness. EAGLES definitively demonstrated no increase in neuropsychiatric adverse events (leading the FDA to remove the boxed warning in 2016) and confirmed equivalent cardiovascular safety across all active treatment arms.
Common Adverse Effects : Nausea occurs in approximately 30% of patients. Clinicians should instruct patients to take varenicline with a full meal and a large glass of water. Other common side effects include abnormal/vivid dreams and insomnia.
- 3. Bupropion Hydrochloride Sustained-Release (Zyban / Wellbutrin SR)
- Mechanism of Action
Bupropion SR is a monocyclic aminoketone antidepressant that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) and a non-competitive antagonist at nicotinic acetylcholine receptors. By inhibiting the neuronal reuptake of dopamine and norepinephrine in the central nervous system, bupropion mimics nicotine's neurochemical effects, mitigating withdrawal and reducing craving frequency.
Dosing Titration
Therapy begins 1 to 2 weeks before the target quit date to achieve steady-state therapeutic plasma concentrations:
Days 1 to 3 : 150 mg orally once daily in the morning.
Day 4 through Week 7–12 : 150 mg orally twice daily (doses must be separated by at least 8 hours to minimize seizure risk; the second dose should be taken in late afternoon rather than bedtime to prevent insomnia).
Clinical Profile & Weight Gain Mitigation
Weight Gain Delay : Bupropion is uniquely beneficial for patients concerned about post-cessation weight gain, as it significantly delays weight accumulation during active therapy.
Comorbid Depression : Highly favorable for patients with coexisting depressive symptoms or seasonal affective disorder.
Absolute Contraindications and Warnings
Seizure Disorders : Bupropion lowers the seizure threshold in a dose-dependent manner (seizure incidence ~0.1% at 300 mg/day). It is strictly contraindicated in patients with active epilepsy or any history of seizures.
Eating Disorders : Contraindicated in patients with a current or prior diagnosis of anorexia nervosa or bulimia , due to an increased risk of seizures.
Abrupt Substance Withdrawal : Contraindicated during abrupt withdrawal from alcohol, benzodiazepines, or other sedatives.
MAO Inhibitors : Must not be used concurrently with or within 14 days of discontinuing monoamine oxidase inhibitors.
Blood Pressure Monitoring : Bupropion can induce mild-to-moderate elevations in resting blood pressure; monitor resting blood pressure regularly during cardiac rehabilitation.
Comparison of First-Line Tobacco Cessation Pharmacotherapies
Medication Primary Mechanism Standard Dosing Protocol Common Adverse Effects Clinical Pearls & Contraindications
Nicotine Patch Continuous transdermal nicotine >10 cigs: 21 mg x 4–6 wk, then 14 mg x 2 wk, 7 mg x 2 wk. ≤10 cigs: Start 14 mg Local skin erythema, insomnia, vivid dreams Rotate sites daily. Remove at bedtime if sleep disrupted. Combine with short NRT.
Nicotine Gum / Lozenge Transmucosal buccal absorption TTFC ≤30 min: 4 mg. TTFC >30 min: 2 mg. Max 20–24 pieces/day Dyspepsia, hiccups, nausea, jaw fatigue Chew-and-park technique. Avoid acidic drinks 15 min before/during use.
Varenicline (Chantix) α4β2 partial agonist & antagonist Days 1–3: 0.5 mg daily. Days 4–7: 0.5 mg BID. Days 8+: 1.0 mg BID for 12 wk Nausea (~30%), abnormal dreams, headache, insomnia Highest single-agent quit rate (30–35%). EVITA/CATS trials confirmed safety in ACS. Take with food & water.
Bupropion SR (Zyban) Dopamine / norepinephrine reuptake inhibitor Days 1–3: 150 mg daily. Days 4+: 150 mg BID (≥8 hr apart) for 7–12 wk Insomnia, dry mouth, tremor, mild BP elevation Delays post-quit weight gain. Contraindicated in seizure disorders and eating disorders .
Realistic Clinical Scenario: Pharmacotherapy Selection in Post-ACS Patient
Clinical Scenario : A 56-year-old male is enrolled in Phase II cardiac rehabilitation 3 weeks after an acute anterior STEMI treated with a drug-eluting stent to the LAD. He smoked 25 cigarettes per day for 30 years and smoked his first cigarette within 5 minutes of waking. He has mild hypertension (BP 132/84 mmHg on carvedilol and ramipril) and no history of seizures, psychiatric illness, or renal disease. He is highly motivated to quit but reports extreme anxiety and failed cold-turkey attempts in the past.
Clinical Decision-Making :
Nicotine Dependence : TTFC <30 minutes confirms severe physical dependence.
Evidence-Based Selection : The CCRP nurse and medical director discuss first-line options. Given his recent STEMI, the team reviews the EVITA trial , which confirmed that varenicline initiated post-ACS is safe, does not increase cardiovascular adverse events, and offers superior long-term abstinence compared to placebo.
Prescription & Education : Varenicline is initiated with standard titration: 0.5 mg daily for 3 days, 0.5 mg twice daily for 4 days, then 1.0 mg twice daily for 12 weeks. The patient is instructed to take doses after meals with a full glass of water to avoid nausea. Because of high breakthrough anxiety, he is also provided with short-acting 4 mg nicotine lozenges to carry during exercise sessions for acute distress.